Immunogenetics

, Volume 55, Issue 6, pp 362–369 | Cite as

Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection

  • Susanne Knapp
  • Branwen J. W. Hennig
  • Angela J. Frodsham
  • Lyna Zhang
  • Simon Hellier
  • Mark Wright
  • Rob Goldin
  • Adrian V. S. Hill
  • Howard C. Thomas
  • Mark R. Thursz
Original Paper

Abstract

The natural outcome and response to treatment in hepatitis C virus (HCV) infection varies between individuals. Whereas some variation may be attributable to viral and environmental variables, it is probable that host genetic background also plays a significant role. Interleukin (IL)-10 has a key function in the regulation of cellular immune responses and in the suppression of pro-inflammatory cytokine secretion. Functional polymorphisms in the IL-10 gene have been described. We investigated the role of these polymorphisms in the outcome of HCV infection, treatment response and development of fibrosis in a case-control association study. Self-limiting infection was associated with the IL-10 (−592) AA genotype (OR=2.05; P=0.028). Persistent infection was associated with the IL-10 (−1082) GG genotype (OR=0.48; P=0.018). Sustained response to interferon therapy was associated with the IL-10 (−1082) GG genotype (OR=2.28; P=0.005) and the haplotype GCC (OR=2.27; P=0.020). The IL-10 (−1082) AA genotype and the ATA/ATA and ACC/ACC homozygous haplotypes were more frequent among patients with rapid fibrosis. Furthermore, the microsatellites IL-10.R and IL-10.G were associated with interferon response with IL-10R.2 conveying susceptibility (OR=1.80; P=0.034), and IL-10R.3 and IL-10.G13 being protective (OR=0.47; P=0.003 and OR=0.59; P=0.042, respectively). We conclude that polymorphisms in the IL-10 promoter appear to have some influence on the outcome of HCV infection, treatment and development of fibrosis.

Keywords

Self-limiting infection Interferon Fibrosis Genotype Disease association Hepatitis C 

Notes

Acknowledgements

HENCORE is the Hepatitis C European Network for Cooperative Research. The participants were: Howards C Thomas, Mark R Thursz (Faculty of Medicine, Imperial College School of Medicine at St Mary's Hospital, Praed Street, London W2 1NY, UK), Pierre Pradat PhD, Christian Trepo (Hopitaux de Lyon, 1 Place de l'Hopital, 69288 Lyon Cedex 02, France), Juan Esteban MD (Hospital General Valle Hebron, Pasea Valle, Hebron S/U o8035, Barcelona, Spain), Stephanos Hadziyannis MD (University of Athens Medical School, 2nd Department of Medicine, Hippokration Hospital, 114 Vasilissis Sophias Avenue, Athens 610, Greece), Michael Manns PhD, Hans Tillmann MD (Medizinische Hochschule Hannover, Carl Neuburg Strasse 1, 30623 Hannover, Germany), Alfredo Alberti MD, Liliana Chemello MD (Department of Clinical and Experimental Medicine, Via Guistiniani 2, 35126 Padua, Italy), Giorgio Saracco MD, Mario Rizzetto PhD (Department of Gastroenterology, Molinette Hospital, Turin, Italy), Jean-Henrik Braconier MD (Department of Infectious Diseases, University Hospital, Lund, Sweden). This work was generously supported by Roche Discovery, Welwyn, UK and the Charmot-Horton Foundation. M.W. is a Medical Research Council of Great Britain clinical training fellow. A.V.S.H. is a Wellcome Trust Principal Fellow.

References

  1. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, Miller JK, Gerber MA, Sampliner RE, et al (1992) The natural history of community acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team (see comments). N Engl J Med 327:1899–1905PubMedGoogle Scholar
  2. Constantini PK, Wawrzynowicz-Syczewska M, Clare M, Boron-Kaczmarska A, McFarlane IG, Cramp ME, Donaldson PT (2002) Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy. Liver 22:404–412CrossRefPubMedGoogle Scholar
  3. Cramp ME, Carucci P, Underhill J, Naoumov NV, Williams R, Donaldson PT (1998a) Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia. J Hepatol 29:207–213CrossRefPubMedGoogle Scholar
  4. Cramp ME, Rossol S, Carucci P, Williams R, Naumov NV, Donaldson PT (1998b) The influence of the HLA class II allele DQB1*0301 on HCV specific T helper cell responses. J Hepatol 28:94CrossRefGoogle Scholar
  5. D'Alfonso S, Rampi M, Rolando V, Giordano M, Momigliano-Richiardi P (2000) New polymorphisms in the IL-10 promoter region. Genes Immun 1:231–233CrossRefPubMedGoogle Scholar
  6. Davis GL, Lau JY (1997) Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 26:122S–127SPubMedGoogle Scholar
  7. Diepolder HM, Zachoval R, Hoffmann RM, Jung MC, Gerlach T, Pape GR (1996) The role of hepatitis C virus specific CD4+ T lymphocytes in acute and chronic hepatitis C. J Mol Med 74:583–588CrossRefPubMedGoogle Scholar
  8. Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE (1999) Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 30:526–530PubMedGoogle Scholar
  9. Eskdale J, Gallagher G (1995) A polymorphic dinucleotide repeat in the human IL-10 promoter. Immunogenetics 42:444–445PubMedGoogle Scholar
  10. Eskdale J, Kube D, Gallagher G (1996) A second polymorphic dinucleotide repeat in the 5′ flanking region of the human IL10 gene. Immunogenetics 45:82–83CrossRefPubMedGoogle Scholar
  11. Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, Huizinga TW (1998) Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA 95:9465–9470CrossRefPubMedGoogle Scholar
  12. Eskdale J, Keijsers V, Huizinga T, Gallagher G (1999) Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus. Genes Immun 1:151–155CrossRefPubMedGoogle Scholar
  13. Fickenscher H, Hor S, Kupers H, Knappe A, Wittmann S, Sticht H (2002) The interleukin-10 family of cytokines. Trends Immunol 23:89–96CrossRefPubMedGoogle Scholar
  14. Germer S, Holland MJ, Higuchi R (2000) High-throughput SNP allele-frequency determination in pooled DNA samples by kinetic PCR. Genome Res 10:258–266PubMedGoogle Scholar
  15. Gibson AW, Edberg JC, Wu J, Westendorp RG, Huizinga TW, Kimberly RP (2001) Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol 166:3915–3922PubMedGoogle Scholar
  16. Godkin A, Jeanguet N, Thursz M, Openshaw P, Thomas H (2001) Characterization of novel HLA-DR11-restricted HCV epitopes reveals both qualitative and quantitative differences in HCV-specific CD4+ T cell responses in chronically infected and nonviremic patients. Eur J Immunol 31:1438–1446CrossRefPubMedGoogle Scholar
  17. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, Park Y, Jones EA (1986) Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 315:1575–1578PubMedGoogle Scholar
  18. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG (2001) Replication validity of genetic association studies. Nat Genet 29:306–309CrossRefPubMedGoogle Scholar
  19. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN, et al (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22:696–699CrossRefPubMedGoogle Scholar
  20. Kenny Walsh E (1999) Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 340:1228–1233CrossRefPubMedGoogle Scholar
  21. Lau JY, Tam RC, Liang TJ, Hong Z (2002) Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35:1002–1009CrossRefPubMedGoogle Scholar
  22. Lio D, Caruso C, Di Stefano R, Colonna RG, Ferraro D, Scola L, Crivello A, Licata A, Valenza LM, Candore G, Craxi A, Almasio PL (2003) IL-10 and TNF-alpha polymorphisms and the recovery from HCV infection. Hum Immunol 64:674–680CrossRefPubMedGoogle Scholar
  23. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958–965CrossRefPubMedGoogle Scholar
  24. Marcellin P (1999) Hepatitis C: the clinical spectrum of the disease. J Hepatol 31 [Suppl 1]:9–16Google Scholar
  25. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group (see comments). N Engl J Med 339:1485–1492PubMedGoogle Scholar
  26. Moore KW, O'Garra A, de Waal MR, Vieira P, Mosmann TR (1993) Interleukin-10. Annu Rev Immunol 11:165–190PubMedGoogle Scholar
  27. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, Purdie DM, Jonsson JR (2000) Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 31:828–833PubMedGoogle Scholar
  28. Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349:825–832CrossRefPubMedGoogle Scholar
  29. Rees LE, Wood NA, Gillespie KM, Lai KN, Gaston K, Mathieson PW (2002) The interleukin-10-1082 G/A polymorphism: allele frequency in different populations and functional significance. Cell Mol Life Sci 59:560–569CrossRefGoogle Scholar
  30. Reuss E, Fimmers R, Kruger A, Becker C, Rittner C, Hohler T (2002) Differential regulation of interleukin-10 production by genetic and environmental factors— a twin study. Genes Immun 3:407–413CrossRefPubMedGoogle Scholar
  31. Rothman KJ (1990) No adjustments are needed for multiple comparisons. Epidemiology 1:43–46PubMedGoogle Scholar
  32. Seeff LB, Buskell Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, Gitnick G, Knodell RG, Perrillo RP, et al (1992) Long-term mortality after transfusionassociated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med 327:1906–1911PubMedGoogle Scholar
  33. Sham PC, Curtis D (1995) MOnte Caro tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 59:97–105PubMedGoogle Scholar
  34. Thursz MR, Yallop R, Goldin R, Trepo C, Thomas HC (1999) Influence of MHC class II genotype on outcome of infection with hepatitis C virus. Lancet 354:2119–2124PubMedGoogle Scholar
  35. Tong MJ, el Farra NS, Reikes AR, Co RL (1995) Clinical outcomes after transfusionassociated hepatitis C (see comments). N Engl J Med 332:1463–1466CrossRefPubMedGoogle Scholar
  36. Touzet S, Kraemer L, Colin C, Pradat P, Lanoir D, Bailly F, Coppola RC, Sauleda S, Thursz MR, Tillmann H, Alberti A, Braconier JH, Esteban JI, Hadziyannis SJ, Manns MP, Saracco G, Thomas HC, Trepo C (2000) Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative Research. Eur J Gastroenterol. Hepatol 12:667–678Google Scholar
  37. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV (1997) An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24:1–8Google Scholar
  38. Vidigal PG, Germer JJ, Zein NN (2002) Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol 36:271–277CrossRefPubMedGoogle Scholar
  39. Westendorp R, Langermans J, Huizinga T, Elouali A, Verweij C, Boomsma D, Vandenbrouke J (1997) Genetic influence on cytokine production and fatal meningococcal disease. Lancet 349:170–173CrossRefPubMedGoogle Scholar
  40. Wright M, Goldin R, Fabre A, Lloyd J, Thomas H, Trepo C, Pradat P, Thursz M (2003) Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut 52:574–579CrossRefPubMedGoogle Scholar
  41. Yee LJ, Tang J, Gibson AW, Kimberly R, Van Leeuwen DJ, Kaslow RA (2001) Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 33:708–712CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Susanne Knapp
    • 1
  • Branwen J. W. Hennig
    • 2
  • Angela J. Frodsham
    • 2
  • Lyna Zhang
    • 2
  • Simon Hellier
    • 2
  • Mark Wright
    • 1
  • Rob Goldin
    • 1
  • Adrian V. S. Hill
    • 2
  • Howard C. Thomas
    • 1
  • Mark R. Thursz
    • 1
  1. 1.Faculty of Medicine, Imperial CollegeSt Mary's Hospital CampusLondonUK
  2. 2.Wellcome Trust Centre for Human GeneticsUniversity of OxfordOxfordUK

Personalised recommendations